

ADVANTAGES OF ADIPOSE DERIVED STEM CELLS (ADSC'S) OVER BONE MARROW - MESENCHYMAL STEM CELLS AND UMBILICAL CORD-MESENCHYMAL STEM CELLS IN REGENERATIVE THERAPIES-A SYSTEMATIC REVIEW

*¹Dr. Kulvinder Kochar Kaur, ²Dr. Gautam Allahbadia and ³Dr. Mandeep Singh

¹Centre for Human Reproduction 721, G.T.B. Nagar Jalandhar-144001 Punjab, India.

²Scientific Director Ex-Rotunda-A Centre for Human Reproduction 672, Kalpak Garden, Perry Cross Road, Near Otter's Club, Bandra (W)-400040 Mumbai, India.

³Consultant Neurologist Swami Satyanand Hospital Near Nawi Kachehri, Baradri, Ladowali Road, Jalandhar Punjab India.

Received date: 01 December 2020

Revised date: 22 December 2020

Accepted date: 12 January 2021

*Corresponding author: Dr. Kulvinder Kochar Kaur

Centre for Human Reproduction 721, G.T.B. Nagar Jalandhar-144001 Punjab, India.

ABSTRACT

With the gradual work on stem cells via bone marrow(BM)or umbilical cord human mesenchymal stem(UC-MSCs) cells finally it has been found that the Human adipose-tissue(AT) constitutes the best source of stem cells in view of its acceptance presence in plenty and much less pain during retrieval as compared to other sources. Adipose derived stem cells(ADSC's)can get maintained as well as expanded within culture for long time without getting rid of their capacity to differentiate and hence yielding great cell quantities that are getting used exceedingly for cell therapy reasons. A lot of outcomes of ADSC's-based cell therapies products showed sufficient effect as well as lot of efficiency in certain clinical reasons for autologous as well as allogenic settings. Thus being thought of as potential ways of replacement, repair as well as regeneration of injured cells. Here we have reviewed these advantages and probable uses like wound repair, cardiac problems, Neurodegenerative problems, radiation injuries, autoimmune diseases after having reviewed MSC's earlier from other sources and embryonic totipotent stem cells.

KEYWORDS: Adipose derived stem cells(ADSC's); mesenchymal stem cells; Neurodegenerative disease; cardiovascular disease; wound healing ;bone/cartilage repair; autologous.

1. INTRODUCTION

Within the adipose tissue (AT), multipotent mesenchymal stem / stromal cells (MSCs) have been obtained that can get reproduced by which our belief regarding AT has drastically changed. These cells got identified within the stromal vascular fraction (SVF), as well as were isolated in the same manner from bone marrow (BM), have characteristics of being plastic, adherent as well as typical MSCs because of which they are called adipose derived stem cells (ADSC's).^[1,2] These ADSC's have adipogenic, osteogenic, chondrogenic, myogenic, as well as neurogenic potential *in vitro*.^[3] This plasticity as well as multipotency has stimulated lot of research in recent times. ADSC's are thought to be tools for replacement, repair along with regeneration of dead or damaged cells. These cells were included for clinical investigations in relation to therapeutic approaches.^[1,4,5]

Regarding haematopoietic cells (HSCs), the formation of treatment strategies that confer greater efficiency and safety has become challenging regarding invasive collection as well as administration, clinical results along with treatment cost. Actually BM, Umbilical Cord(UC)-mesenchymal stem cells(UC-MSCs) as well as ADSC's got utilized in the form of stem cell-dependent treatments regarding regenerative medicine. The utilization of enriched ADSC's or cell assisted Lipotransfer (CAL) is mostly accepted by plastic surgeons and it was first utilized for overcoming fat necrosis as well as escalate fat grafting, particularly in cosmetic remodelling.^[6,7] Right now both preclinical as well as clinical applications of fat, (SVF, or enriched ADSC's for therapy of a variety of disease offer a great promise. The work done has been with regards to wound defects, vascular ischemia, regeneration of bone, neurodegenerative diseases, cartilage tissue deficiencies,

cardiovascular injuries, as well as graft versus host disease (GVHD).^[7,8-12]

Further the widespread clinical use of ADSC's is based on the way of utilizing them. Getting purified or being within their microenvironment is crucial for their therapeutic outcomes and might ensure better understanding as far as the induced side effects are concerned. Second issue is the shifting of ADSC's use from autologous to allogenic setting. Development of biotechnological techniques have improved the utility of highly purified ADSC's along with newly performed cells,^[13] getting proposed for the allogenic setting when autologous cells are not available. This way ADSC's might be having a primary part in regenerative medicine in this 21st century. Nevertheless risk factors which are associated with manipulation as well as cryopreservation, their concentration, as well as route of administration are controlled and standardized.

Earlier we have reviewed the role of totipotent Embryonic stem cells and that of mesenchymal stem cells (MSC's) in case of Type 1 diabetes and regenerative medicine.^[14-16] Here we conducted a systematic review on ADSC's in view of advantages that they possess over BM and Umbilical Cord UC-mesenchymal stem cells(MSCs).

Methods We did a Pub med search from 1975 till date regarding ADSC'S using the MeSH Term ; MSCs; ADSC'S; characteristics ;use in wound healing;cardiovascular system (CVS) diseases; Autoimmune diseases ;graft versus host diseases (GVHD) neurodegenerative diseases ;radiation injuries.

RESULTS AND DISCUSSION

We found a total of 10,599 articles out of which we used 106 articles for this review. No meta analysis was done.


2. Adipose Derived Stem Cells (ADSC'c)

Various terms were hypothesized for these cells from different researches-i)processed lipoaspirates ii)AD adult SC's, adipose mesenchymal stem cells, Adipose Derived Stromal /Stem Cells, Adipose Stromal Cells. Thus, the International Federation of Adipose Therapeutics (IFATs) used the ADSC' name to have more common name.

Right now they get collected from the subcutaneous AT,^[17] that helps in getting them fast in large numbers having a high cellular activity.^[2,18] They consist of stromal vascular fraction and is thought to be the best one in all tissues^[19] occasionally almost 30%.^[20] Mutually, the IFATs and ISCT have accepted, same regarding smaller expression amount of stromal associated markers CD13, CD29, CD44, CD73, CD90,

CD105, CD106 in the SVF cohort on the converse regarding cultured ADSCs. These expressions were repeatedly marked by late ADSC passage.^[21] The particular expression of CD10, CD 36 and CD 106 can differentiate them from the ones from BM.^[22] With ADSC research, being mainly conducted with the utilization of culture-expanded cells, has resulted in current agreement of CD 34 as the marker for the ADSCs identified. Hence interesting things of CD 34 biology needs to be further explored and inner sight got. Correlation between CD 34 marker with hypoxia has also been documented. CD 34 may represent niche-particular marker for progenitors, and hypoxia is associated with the sustenance of adult stem cells.^[23] As per Sengenesis et al. The human SVF cell population that had CD 34 were enriched in ADSC s in contrast to BM-MSCs.^[24] But the expression of this antigen was only documented in the early culture passage.^[25] Additionally the presence of CD 34 + subpopulation was an indicator of a minimum of 20% freshly identified SVFs.^[26] Other surface antigen Stro1 that is typical BM-MSCs related antigen, was documented separately within ADSC in the publications.^[2] Moreover as per another publication ADSC might get particularly found utilizing the CD271 marker,^[27] in which the expression has been sustained in aged persons and correlates with marked proliferative and differentiating capacities.^[28] ADSC further liberate trophic factors which control cell growth and exhibit lipolytic effects following β -adrenergic agents exposure and activated protein kinase phosphorylation in case of tumor necrosis.^[39]


Adipose Derived Stem Cells from younger donors display a > multiplication rate as compared to elderly people, although they had sustained ability with aging.^[30] Hence the advantage over BM-MSCs. Furthermore ADSCs sustained their ability to differentiate into cells of mesodermal origin, usually recognized for their low immunogenicity, with manipulative actions.^[31] HLADR protein is expressed by less than 1% on their surface causing immunosuppression actions and hence increasing their usefulness clinically in allogenic transplantation along with treating resistant immune disorders. UC-MSC's also were documented as being more primitive as compared to ADSCs,^[1] and ADSCs having validated their advantages as far as numbers available with adequate cell numbers. Regarding BM, ADSCs cell growth halted during passage 11-12, but showed lesser doubling of their cohort than BM and umbilical cord- mesenchymal stem cells (UC-MSCs), thus being shorter but more multiplication capacity than UC-MSCs.^[1] All these properties helped in motivating their use in tissue repair, in which cell multiplication, angiogenesis along with antiinflammatory features were anticipated to take place fast in the injured areas(figure1).[see ref 32].



Legend for Figure 1: Courtesy ref no-32-Immuno-modulatory effects of adipose derived stem cells (ADSCs). ADSCs stimulate macrophage change immunity and inhibit T and Dendritic cells, inducing angiogenesis, a decrease in apoptosis and fibrosis with an increase in anti-inflammation process. Interleukin-1 α , -6, -10 (IL-1 α , -6, -10, -13), TNF- α (Tumor Necrosis Factor- α), TGF- β (Transforming Growth Factor- β), TLR2, TLR4 (Toll Like Receptor 2, 4), VEGF (Vascular Endothelial Growth Factor), b-FGF (basic Fibroblast Growth Factor).

From other angle 1st finding of ADSCs was by their capacity to differentiate into mesodermal lineages. But multiple observations corroborated the latter with their differentiation into ectodermal along with endodermal germinal layers displaying an edge in making tissue engineering programmes in regenerative medicine. ADSCs also had greater chances of differentiation into the adipogenic lineage as compared to BM and UC-

MSCs, with their multiple potency understood for ectodermal along with endodermal repair of the tissues.^[33](figure2) that points that more work is needed for standardizing ADSCs modulation regarding clinical utilization. Still long term expansion as well as activation along with cryopreservation influenced functional nature.^[34]



Legend for Figure 2: Courtesy ref no-32-Secretome of Adipose Derived Stem Cells (ADSCs) that are involved in the mechanisms related to tissue repair and regeneration. ADSCs secrete different growth factors in their microenvironment and other proteins known to induce specific cell differentiation. Interleukin-1, -6, -10 (IL-1, -

6, -10), TNF- α (Tumor Necrosis Factor- α), TGF- β (Transforming Growth Factor- β), TLR2, TLR4 (Toll Like Receptor 2, 4), GDF11 (Growth Differentiation Factor 11), GDF15 (Growth Differentiation Factor 15), G-CSF (Granulocyte-Colony Stimulating Factor), GM-CSF (Granulocyte Monocyte-Colony Stimulating Factor), EGF (Endothelial Growth Factor), VEGF (Vascular Endothelial Growth Factor), IGF (Insulin Growth Factor), b-FGF (basic Fibroblast Growth Factor), PDGF (Platelet Derived Growth Factor), NGF (Nerve Growth Factor), CCL-2 (Chemokine C-C Motif Ligand 2), PEDF (Pigment Epithelium Derived Factor), KGF (Keratinocyte Growth Factor).

2.2 Present Methods in ADSCs-basis for treatment

These are pluripotent /resident SC's which take part and stimulate various biological processes that participate in normal mechanism of tissue repair and functioning all through life. But MSCs appeared to be more adaptive for action at the site, hence more suitable for locally degenerative diseases.

ADSCs are thought to be main components regarding repair, replacement along with regeneration of mortal or injured cells. These cells were utilized for clinical evaluation regarding treatment plans, having all the part of criteria required for cell based treatment, thus they become the maximum adapted cells for doing the initial part during regenerative medicine. ADSCs are present in mammoth amounts and can be obtained by utilization of least invasive work ,have ability of differentiation into maximum cell lineages in an allogenic setting Probable production with recent good manufacturing practices(GMP) guidelines is going on by overcoming various technical problems.

In clinical studies mostly whole stromal vascular fraction (SVF), was utilized with ADSCs that had been obtained either alone or along with biomaterials whether autologous or allogenic. For prevention of misunderstanding regarding utilization of SVF along with its ADSC population obtained with their comparative properties that can give us benefit. ADSCs had the maximum benefit to risk in skin oncohaematology bone and cartilage applications as compared to bone marrow (BM) and Umbilical Cord (UC)- mesenchymal stem cell(MSC's). These cells get utilized for a lot of reasons, including immunomodulation actions (multiple sclerosis[MS], fistula, acute and chronic graft versus host diseases (GVHD), diabetes mellitus(DM1), Crohn's diseases), angiogenic potential (ischaemia, scars, wound repair), along with differentiation capacity (arthritis, cardiac and spinal injury, bone regeneration)[reviewed in [ref 35] for regenerative medicine]. What way is utilized for delivering stem cell implantation has the potential to see what will be the efficacy of the cell therapy.

2.2A. ADSCs Role in Wound Healing and Skin Regeneration

Initially stem cell dependent therapies utilized in wound recovery were done utilizing autologous cultured epidermal autografts(CEA) instead of epidermis . Cellular parts supplementation to these skin substitutes have resulted in good skin looks, as well as function. Utilization of MSCs from variety of places has come out

as a special alternative method for taking care of wounds regarding multiple skin –associated problems to attain natural skin regarding its looks, texture, color as well as metabolic characteristics. Regarding availability, big cell amount present and collecting using a noninvasive technique it has been posited that ADSCs have crossed the problems encountered utilizing CEA. Reason given is repeated open wounds, fragile wounds as far as long time is concerned along with greater scar contractions by stimulating excessive ECM synthesis.^[4] Their capacity to heal chronic wounds, was emphasized via ECM liberation, resulting in proliferation as well as remodelling stage of wound healing.^[5] These cells have been demonstrated to facilitate fat tissue surviving and along with free fat are becoming a proper extra method regarding soft tissue augmentation surgery, like in breast augmentation as well as facial tissue defects.^[6,7]

ADSCs modulated tissue reconstitution ,hence improving the defects within the tissues and enhancing skin regeneration ,aid in cicatrisation and manipulate inflammation, thus facilitating skin healing.^[8] The growth factors as well as anti inflammatory cytokines which they secrete avoided cell apoptosis as well as stimulated neoangiogenesis , especially in treating critical limb reduced blood flow. Multiple researchers have utilized autologous or allogenic ADSCs in the therapy of burns, either alone or together with Epidermal graft, that aids in bettering skin engraftment.

Certain therapeutic progress has been demonstrated while utilizing BM and/or UC-MSC's for getting total remission regarding ulcers, scars and burns therapy.^[35] But the capacity of ADSCs to work via extra proliferation, differentiation as well as paracrine manner has given evidence that they are better regarding use in a lot of ways in this branch.


2.2B. ADSCs in Autoimmune Disorders

ADSCs have been used in therapy of many Autoimmune diseases. They were found to be safe and effective for systemic lupus erythematosus(SLE), systemic sclerosis(SS), Sjogrens syndrome, Scleroderma, and Crohns diseases. Patients with Crohns diseases came with closed fistula following injection of the cells,^[36,37] with betterment of disease , in addition to patients safety . Conversely, a reduction in severity of disease was seen following BM and/or UCB-MSC's therapy and this action seemed to be over determined maybe due to smaller numbers as per the sample size or the small follow up.^[38,39] Still these cells were documented to have maximum importance in therapy as well as avoiding

graft versus host disease[GVHD] occurring from HSC s transplantation.^[40]

ADSCs methods seemed to have safety as well as greater efficiency regarding adverse effects documented. Formatting MSC's transplantation protocols, when

utilizing ADSCs, therapeutic aims may be more selective as regard to subjects with Sjogrens syndrome SLE, polymyositis and Crohns diseases.^[37] (figure3) Even the immunomodulating ability of ADSCs was good when used for T1DM, where new cells that liberated insulin got regenerated.^[41]




Legend for Figure 3: Courtesy ref no-32-herapeutic features of Adipose Derived Stem Cells (ADSCs) in auto-immunes and hematopoietic diseases compared to those of bone marrow (BM)- and umbilical cord (UC)-mesenchymal stem cells (MSCs). The size line is related to the observed effect.

2.2C.ADSCs in Haematological Disorders and GVHD


Therapy of GVHD has been maximally evaluated using BM-MSC's following allogenic HSC transplantation and/or lymphocyte infusion. Infusing allogenic BM-MSC's in adult subjects as well as children with steroid-resistant acute GVHD caused total response with overall survival in maximum subjects following UCB and HSC transplantation with no adverse effects at the time or immediately following MSC's infusion,^[40,42] although higher results were seen with initial BM-MSC's supplementation,^[43] (fig3). In case of cancers BM-MSC's had safe profile and could help in bettering the haematopoietic engraftment,^[44] with same kind of

observations with the utilization of UCB-MSC's in smaller children as well as adult subjects following HSC transplantation,^[45] Increasing the rate of improvement of the haematological system was also seen following infusion at the same time of autologous blood HSC and BM-MSC's in subjects affected by breast cancer who were getting heavy chemotherapy dosing.^[46] Zhang etal .reviewed the role of adipose derived stromal cells in haematopoiesis regulation as well as the insight on the properties of these adipose derived stromal cells (ASC's) along with their current utilization as well as future role of these ASC'S [reviewed in ref 47](see figure 4).



Legend for Figure. 4: Courtesy ref no-47-Mechanisms of ASC-mediated regulation in hematopoiesis. The secretion of a variety of cytokines and chemokines is believed to be the main mechanism by which ASCs regulate hematopoiesis. The molecules secreted by ASCs (e.g. SCF, SDF-1, etc.) can bind to the receptors on HSCs. The secretion of EVs is another possible mechanism. The signaling molecules inside the lipid bilayer contribute to intercellular communication. ECM mediates cell adhesion and signal transduction. The soluble and cell-surface

proteins expressed by ASCs are thought to be involved in ECM remodeling. Several signal pathways can be activated when HSCs are exposed to ASCs, by which ASCs regulate self-renewal, proliferation, and differentiation of HSCs.



Legend for Figure 5: Courtesy ref no-97-Extracellular vesicles mode of action in various tissues.

ADSCs as an alternative also helped in HSC engraftment avoiding both acute as well as chronic GVHD.^[48] These cells could help in total differentiation along with synthesis of mature myeloid as well as B lymphoid cells but could not sustain the longevity of surviving and automatic renewal of HSC, pointing that ADSCs can work for a small time only in aiding in haematopoiesis redevelopment.^[49] In the same way in vitro and in vivo haematopoiesis in mice observations were there.

2.2D. ADSCs in Bone/Cartilage Repair

Other than rest of adult tissue which develop scar tissue following damage, the skeleton goes via healing of the new bone.^[50] A lot of stimulus has been there in the utilization of undifferentiated progenitor cells with the purpose of tissue engineering in view of their capacity to enhance in culture, with differentiation into different cell lineages on culturing in particular growth specifics. Due to these properties, adult stem cells through variety of tissues have got utilized in different cartilage as well as bone rejuvenation. Lot of chondrogenic ability has been displayed by ADSCs in tissue engineering methods.^[51]

The commonly used method of ADSCs is in bone and cartilage regeneration as well as repair that does not come as a shock. Despite BM-MSC's having lot of osteogenic differentiation ability *in vitro*, the BM-MSC's osteogenic repair use *in vivo* is not much, with this use in bone repair is gradually getting taken over by the ADSCs. Similarly clinical usefulness of UCB-MSC's regarding articular cartilage repair not much relevance found with single clinical trial done.^[52]

Either by themselves or together with a scaffold ADSCs have shown effectiveness in improving maxillary defects followed by bone regeneration.^[53] Following trauma calvarial deficiencies also got corrected with autologous ADSCs as well as calvarial continuation with bone regeneration got. Their capacity of liberating anti-inflammatory factors along with reduced pro-inflammatory effects that allows them to be very

lucrative and effective therapy in intervertebral disc injuries, rheumatoid arthritis, osteoarthritis as well as tendon damages.^[10,54] Therapeutic benefit of ADSCs was greater than seen in therapy of cartilage problems with higher case reports in these therapies in publications.^[9]

2.2E. Role of ADSCs on cardiovascular system (CVS) and Muscular Diseases

Marked ability of getting regenerated is a property of adult skeletal muscles. For the postnatal growth it is the muscle satellite cells that take care of the main recovery of the adult skeletal muscles. Proof is there that it is skeletal muscles which affect aging. On the basis of aging, decrease in skeletal muscles, strength, as well as capacity to bear at the time of aging occurs physiologically with different processes that may enhance this function. Capillaries have an important role in the mode that is behind the close association among blood flow as well as metabolism of skeletal muscles mass. Conversely to the skeletal muscles myocardium possesses minimum ability to regenerate [reviewed in references].^[55,58] Though the neonatal heart of mammals has marked regeneration capacity via proliferation of myocardium till the postnatal day 7. One common thing that all organisms have is the capacity to regenerate heart in oxygenated state. It has been posited that the shifting from the oxygen (O₂) high postnatal surroundings represents the upstream signal, that causes cell cycle arrest of cardiomyocytes.^[59]

Cardiac muscle has minimal ability to proliferate and thus regenerative strategies are required. Direct programming of fibroblasts can be done to cardiomyocytes by overexpression of 3 cardiac-specific transcription factors (Gata4, Mef2c, Tbx5).^[60] It was documented that somatic cells might get directly reprogrammed to other differentiated outcomes without going via stem/progenitor cell stage. That human skin fibroblasts exposed to a Radio Electric Asymmetric Conveyer (REAC) gives its commitment to cardiac and skeletal muscle lineages,^[61] is there.

Good processes that result in stimulating differentiation to cardiomyocytes which develop homogenous cardiomyocytes populations of enough numbers is a prerequisite of the newer applications. Isolation of MSC's can be done from variety of human tissues that possess multipotential as well as immunomodulatory properties for helping the repair of injured tissues. Effectiveness and possibility regarding CVD treatment from separate origin as well as tissue obtained MSC's.^[62] This way getting cardiac differentiation, stem cell – dependent treatments have come out as efficient methods of treatment of CVD.^[63] There is proof that paracrine factors liberated mainly modulate the treatment efficiency of transplanted stem cells, of which what is important is that microRNA's exist in the secreted exosomes.^[64] These MSC's-obtained exosomal microRNA's deliver cardioprotection via induction of angiogenesis in ischemic heart.^[65]

Different studies using small animals have utilized intramyocardial injections. But still limitation displayed by these injections is engraftment of cells within the infarcted myocardium. For getting over this, some innovative hydrogels have been utilized as delivery ways for ADSCs. MSC's were agreed upon to differentiate into cardiomyocytes *in vitro*,^[66] and show lot of value in cardiomyocytes that are regenerating within myocardial infarction(MI). Autologous as well as allogenic BM-MSC's which got transplanted into MI subjects ,did not display any adverse effects and enhanced left ventricular working , reduced cardiac arrhythmias ,and enhanced myocardial functioning.^[67,68] Other studies utilized UCB-MSC's in the form of intravenous infusion in patients with heart failure , decreased ejection fraction, as well as enhanced left ventricular functioning in these patients.^[69]

Direct cardiac reprogramming has come out to be innovative method for regenerating injured myocardium by conversion of endogenous cardiac fibroblasts into induced cardiomyocytes -like cells for getting cardiac function back. These fibroblasts replace dead cardiomyocytes resulting in the development of fibrosis as well as myocardial refashioning. Studies are there in connection among ADSCs and fibroblasts .Media conditioned by ADSCs help fibroblasts multiplication, that points that paracrine stimulation of fibroblasts takes place through ADSCs. Same fibroblasts which got cultured in Media conditioned by ADSCs were observed to liberate greater quantities of type1 collagen. From these observations it is clear that the interactions among these might contribute remarkably in protection of myocardium.

From alternative way, these ADSCs might turn out to have more CVS importance, as well as these cells being evaluated in ,multiple clinical trials in the past 10yrs. That time ADSCs were directly delivered into myocardial tissue of patients having MI or ischaemic heart failure without associated events with their utilization being safe as well as having greater efficacy in

improving cardiac function.^[71] Use in animal models also ADSCs showed their efficiency whether delivered via intracoronary, transendocardial, intramyocardial, or intravenous approach.^[19,72]

As far as skeletal muscle is concerned the capacity of regeneration of MSC's still holds controversy with only few human studies documented. But promising outcomes clinically have demonstrated muscle activity improving in patients coming with muscle dystrophies following infusion of UCB-MSC's. But greater than anticipation of paracrine action of these MSC's was there regarding improving cardiac function by escalation of angiogenesis as well as anti-apoptosis, instead of direct differentiation towards cardiomyocytes.^[73] in animal models, ADSCs can get differentiated into skeletal muscle cells as well as enhance the ECM collagen VI deficiency in the congenital muscle dystrophy as well as mice model of Duchenne muscle dystrophies(mdx mice).^[74,75]

2.2F.Role of ADSCs on Neuro Degenerative Diseases

Nervous tissue for long has been thought to give problems in regeneration, as mature neural cells do not proliferate for differentiation. Still insight is not there whether neural stem cells get actively maintained throughout life and regarding exact cellular crosstalk as well as molecular cascades. Adult mammalian brain has atleast 3 areas which are neurogenic, containing a reservoir of neural stem cells;i)the subgranular zone in the hippocampal dentate gyrus, and ii),the subventricular zone around the lateral ventricles i ii) as well as the hypothalamus .Various parts of the neural stem cells niche have been found that control neural stem cells action via giving different signals.^[76] ADSCs can transdifferentiate into neural like cells which have a lot of neuronal qualities like action potential,dopamine liberation as well as that of neurotrophic factors as well as spontaneous postsynaptic current .As per certain recent studies miRNA's may control the neuronal like differentiation of MSC's. miR-21 has been corroborated directly aid to ADSC differentiation.^[77] For ADSC's to become ideal for treatment of neurological diseases therapy ,they must produce enough number of specific factors of functional as well as high quality neural cells . At the time of transdifferentiation into neural cells, xenobiotics or specific factors as well as the corresponding partial methylation or acetylation of genomic areas as well as activation of further transdifferentiation processes stimulate ADSC's.

These ADSC's as well as other MSC's have been posited for innovative therapy of certain neurological diseases like Alzheimer's as well as Parkinson's diseases, stroke, amyotrophic lateral sclerosis (ALS), Huntington's disease, spinal cord injury, traumatic brain injury, as well as MS. These cells have given evidence of their effectiveness to pass via blood brain barrier(BBB) even when intravenous transplanted. Neuronal morphological properties as well as markers were seen following cell infusion either by differentiation into neuron like cells.^[33]

or fusion of endogenous cells.^[78] But their therapeutic advantages seemed to be stimulated via secreted proteins.^[11,12] Proteomic evaluation have corroborated that BM as well as UC-MSC's conditioned media stimulated Neuronal differentiation, neurite outgrowth through dorsal root ganglion explants whereas ADSC's demonstrated >axonal growth.^[11] Especially ADSC's paracrine activity was not the one only causing the liberation of nerve growth factors as well as neurotrophic mediators which participate in nerve regeneration,^[12] that adds to the complexity of the microenvironment as well as nerve progenitor 's interactions . When utilizing at either autologous or allogenic set up at a low or high doses that got infused as well as with lot of infusions, neuroprotective as well as immunomodulatory effects were associated with MSC's via 3 sources that causes a reduction in pathological features as well as relief of the disability of MSC's immunomodulation.

These therapeutic characteristics of BM -MSC's have given advantage to Parkinson's disease patients.^[79] as well as these outcomes have stimulated other current controlled phase study . Besides clinical benefit has been seen in patients with ALS as well as stroke on utilizing modified BM -MSC's.^[80,81] Recent research evaluating the BM -MSC's-derived neural progenitor on patients presenting with MS has shown safety as well as tolerability without any serious side effects.^[82,83] With the use of an alternative conditioned media from BM -MSC's culture, followed by BM -MSC's transplantation, potentiated the clinical benefit as well as these abrogative action seems to be based on IL-6,IL-8 as well as vascular endothelial growth factor(VEGF) conditioned the media amounts.^[84] Similarly Li et al., showed previously that a shift from Th1 to Th2immunity advantage seen for ADSC's was definitely their paracrine action following transplantation.^[85] The secreted factors may directly work neuroprotection or via immunomodulation effecting the expression or secretion of a lot of mediators involved in angiogenesis, synaptogenesis, gliogenesis as well as neurogenesis.^[86] Other treatment methods might do cell combination for getting greater neurological functional enhancement,^[87] or using VEGF, Angiogenin (ANG), as well as transcription growth factor beta (TGF β) as anticipating biomarkers for cell treatments efficacy and choice of patients.^[88] Besides that ADSC's have been advocated for retinal degenerative diseases as well as renal transplantation, although they are still in early stages regarding ADSC's differentiation potency as well as immunosuppressive capacity in tissue repair.

2.2G.Role of ADSCs on Radiation Damages

Be it interventional radiological, radiotherapy or cardiological procedures an escalation of Radiation damages on wounds as well as other organs keep on occurring.^[89-92] One cannot treat conventionally like flap surgery or skin grafting with chronic Radiation wounds in view of tissue ischemia as well as fibrosis.^[93] Ischemia

occurs secondary to improper vasculature as well as incompetent vessels present within irradiated tissues.^[94] Radiated skin demonstrates erythema as well as abnormal pigmentation. If a radiation wound is there further necrosis complicates it as well as fibrosis in different organs, like in heart for these stem cell therapies to work

These chronic Radiation wounds might get better by escalating enough blood supply to those tissues. Conversely combined radiotherapy as well as chemotherapy have been a major progress towards therapeutic treatment of cancer therapy. But combination of doxorubicin (DXR) as well as cardiac irradiation might precipitate unexpected congestive cardiac failure(CCF).^[95]

In therapy of chronic Radiation wounds ADSC's have shown >advantage as well as in myocardial diseases. Delivering them causes greater blood perfusion as well as capillary density in irradiated wound.^[91] Viability of irradiated skin flap enhances on therapy with ADSC's injection in association with enhanced vascularity in the flaps injected with ADSC's. On the cellular level these ADSC's stimulated fibroblasts proliferation as well as enhanced expression of a variety of cytokines like VEGF.^[92]

3. Challenges associated with autologous as well as Allogenic Clinical Utility of ADSC's

The property of stemness , plasticity as well as robustness given to MSC's make them very lucrative adult s stem cells in regenerative medicine . With the number as well as frequency as well as differentiation capability of BM -MSC's, has a negative association with age,^[96,97] elderly patients might not contain effective autologous stem cells, it points that allogeneic stem cells would be needed. ADSC's are phenotypically similar to bothBM- MSC's as well as UC- MSC's on utilizing a panel of 22 surface antigens,^[96] with the gene expression signature appearing to show an upregulation of 24 genes within ADSC's in contrast to BM- MSC's,^[98] with lot of hundred expressing sequence tags of.^[96] Formation of Allogenic method indicates that ADSC's would get isolated via a donor who volunteers ,then get expanded ex vivo, as well as cryopreserved in the form of suitable cell product till tissue repair required. Hence multiple unrelated patients can get treated via a single donor. AT via HLA-identical siblings or cases of haploidentical relations / HLA-screened healthy volunteers is thought as a suitable alternate method & might be best method of collecting/storing till utilized in proper HLA- matched case.

AT itself can help in forming stem cell bank,^[99,100] 2 queries arise i)their use should be practical as well as efficacious(large numbers are required) ii)clinical results need to be identical to the anticipated use. Big promise of ADSC's is that upto 24-48h maintenance is feasible within lipoaspirates,^[40] cryopreserved prior to separation

as well as seeding in culture with stable as well as efficacious capacity to proliferate as well as differentiate,^[101] as compared to fresh BM. USC tissues that are essential for retrieval as well as deriving of MSC's. Hence the banking of Allogenic ADSC's holds lot of promise for regenerative therapies. But for broad use efficacious easy and significantly safe procedures need to be offered for assuring cell quantities that are not contaminated, are functional as well, ADSC's are available as per cGMP. Lot of emphasis is made on this to ensure therapeutic usage.^[102,103] But banking still remains debatable.

It can be suggested that allogenic model might be more lucrative regarding cell therapy industry. But autologous cells usually improve cell therapy immunotherapy rather than allogenic. Other than academic as well as university communities certain biotechnological firms are doing clinical work on ADSC's in many fields. Developed laboratory ADSC's preparation /patented formulas of adult Stem Cells are there for going via examination as well as safety of variety of MSC's therapies for many diseases. Osiris Therapeutics Inc Mesoblast Ltd is working for forming Stem Cells based treatment in Crohn's disease as well as radiation exposure.^[104] But still cost is the limiting factor. As per Gimble et al. one day might arrive when lot of people actually go to donate fat in the "fat drives" akin to "blood drives" altruistically. These clinical grade ADSC's need to be done using standards laid down by GMP.^[105] Further Lelek and Zuba-Sharma have tried to further go upto using extracellular vesicles from ADSC's or UC- MSC's for Regenerative Therapies [reviewed in [ref 106].

CONCLUSIONS

ADSC's are phenotypically similar to both BM- MSC's as well as UC- MSC's on utilizing a panel of 22 surface antigens, with the gene expression signature appearing to show an upregulation of 24 genes within ADSC's in contrast to BM- MSC's., with lot of hundred expressing sequence tags of. The differences as per differentiation potential as well as proliferation capability might also show the incidence as per the microenvironment in relation to their originating tissues. This might answer the query as far as their ex vivo expansion variations have been documented and assures clinical usefulness. Actually, the advantageous outcomes seen on transplantation of SVF might be attributed to its heterogeneity as well as activation of the associated microenvironment which got made up by subpopulations of haematopoietic as well as endothelial progenitors as well as cells. Thus understanding of host associated factors that includes local environment along with proper timing are required for master factors that regulate the fate of ADSC's following infusion. One needs to give attention to patient related factors for design of ADSC' based therapies, in view of their effect on number as well as functional behaviour of these expanded cells. Greater ADSC's purity regulation needs to be stressed as well as find potency assays to assure their regenerative ability.

This ensures finding reproducible as well as consistent standardized cell preparation which have suitability in large scale. Greater expanded cell numbers might be needed when performing actual application as well as variability documented in clinical results might be secondary to variations in the amounts of cells infused. As per Gimble et al. one day might arrive when lot of people actually go to donate fat in the "fat drives" akin to "blood drives" altruistically. These clinical grade ADSC's need to be done using standards laid down by GMP.

Usage of ADSC's appears to have > role as compared to BM- MSC's in regenerative medicine, since there is ease of collection as well as greater numbers. Cell based treatments for regenerative medicine have to meet least criteria as in other medical therapies. Despite everything before routine use is done some queries need to have solution. Doubts of reports exist regarding proliferation of cancer cells meaning they might activate pre-existing growths. Thus proper check up of patients needs to be done and they should not to be used in any case of cancers.

REFERENCES

1. Jin HJ, Bae YK, Kim M, Kwon SJ, Jeon HB, Choi SJ, et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose-tissue and Umbilical Cord blood as sources of cell therapy. *Int J Mol Sci.*, 2013; 14: 17986-18001.
2. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose-tissue is a source of multipotent stem cells. *Mol Biol Cell*, 2002; 13: 4279-295.
3. Vermetto M, Trottier V, Menard V, Saint-Pierre L, Roy P, Fradette J. Production of a new tissue engineered adipose substitute from human adipose derived stromal cells. *Biomaterials*, 2007; 28: 2850-860.
4. Trottier V, Maceau-Fortier G, Germain L, Vincent C, Fradette J. IFATS collection: Using human adipose-tissue derived stem cells for the production of new skin substitutes. *Stem Cells*, 2008; 26: 2713-723.
5. Heydig K, Riis P, Pennisi CP, Zachar V, Fink T. Implications of extracellular matrix production by adipose-tissue derived stem cells for development of wound healing therapies. *Int J Mol Sci.*, 2017; 18: 1167.
6. Wang L, Lu Y, Luo X, Fu MG, Hu X, Dong H, et al. Cell-assisted lipotransfer for breast augmentation: a report of 18 patients. *Clin J Plast*, 2012; 28: 1-6.
7. Koh KS, Oh TS, Kim H, Chung IW, Lee KW, Lee HB, et al. Clinical application of human adipose-tissue derived mesenchymal stem cells in progressive hemifacial atrophy (Parry Romberg disease) with microfat grafting technique using 3-dimensional computed tomography and 3-

- dimensional camera. *Ann Plast Surg.*, 2012; 69: 331-37.
8. Rigotti G, Charles –de –Sa L, Gontijo –do –Amorin NF, Takiya CM, Amable MR, Borojevic R, et al. Expanded stem cells, stromal vascular fraction and platelet rich plasma enriched fat: comparing results of different facial rejuvenation approaches in a clinical trial. *Aesthetic Surg J*, 2016; 36: 261-70.
 9. Pak J, Lee JH, Pak N, Pak Y, Park KS, Jeon JH, et al. Cartilage regeneration in humans with adipose tissue –derived stem and adipose stromal vascular fraction cells Updated status. *Int J Mol Sci.*, 2018; 19: 2146.
 10. Im GI. Regeneration of articular cartilage using adipose stem cells. *J Biomed Mater Res A*, 2016; 104: 1830-844.
 11. Assuncao –Silva RC, Mendes-Pinheiro B, Patricio P, Behie LA, Teixeira FG, et al. Exploiting the impact of the secretome of MSCs isolated from different tissue sources on neuronal differentiation and axonal growth *Biochimie*, 2018; 155: 83-91.
 12. Widge row AD, Salibian AA, Lalezari S, Evans GRD. Neuromodulatory nerve regeneration: adipose tissue –derived stem cells and neurotrophic mediation in peripheral nerve regeneration. *J Neurosci Res.*, 2013; 91: 1517-524.
 13. Duckers HJ, Pinkernell K, Milstein AM, Hefrick MH. The bedside Cellution system for isolation of adipose derived regenerative cells. *EuroIntervention*, 2006; 2: 395-98.
 14. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Advances in Stem Cell Research over a Period of Time with Therapeutic Applications: Special Emphasis on Parthenogenetic Embryonic Stem Cells and Induced Pluripotent Stem Cells. *J Stem Cell Research*, 2016; 53340170: 1-13.
 15. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Therapeutic Application of Utilizing resident Resident stem cells in Regenerative Medicine. *Source J Stem Cells*, 2017; 1: 1-14.
 16. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Mesenchymal Stem Cells: Novel Therapeutic Option Besides their Stem Cell Properties-Utilizing the Niche Effect. *Stem Cell Res Ther*, 2017; 3: S115.
 17. Palumbo P, Miconi G, Cinque B, La Torre C, Lombardi F, Zoccali G, et al. In Vitro evaluation of different methods of handling human liposuction aspirate and their effect on adipocytes and adipose derived stem cells. *J Cell Physiol*, 2015; 230: 1974-81.
 18. Miyagi-Shiohira C, Kurima K, Kobayashi N, Saitoh I, Watanabe M, Noguchi Y, et al. Cryopreservation of adipose derived mesenchymal stem cells. *Cell Med*, 2015; 8: 3-7.
 19. Strem BM, Hicok KC, Zhu M, Wulur I, Alfonso Z, Schreiber RE, et al. Multipotent differentiation of adipose-tissue derived stem cells. *Keio J Med*, 2005; 54: 132-41.
 20. Lataillade JJ, Magne B, Bey E, Leclerc T, Trouillas M. Skin engineering for severe burns. *Transf Clin Biol*, 2017; 24: 245-50.
 21. Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, et al. Immunophenotype of human adipose -derived cells: Temporal changes in stromal associated and stem cell associated markers. *Stem Cells*, 2006; 24: 376-85.
 22. Maumus M, Peyra fitte JA, D'Angelo R, Fournier –Wirth C, Boulomie A, Casteilla L, et al. Native human adipose stromal cells : localization, morphology and phenotype. *Int J Obes*, 2011; 35: 1141-153.
 23. Zhao D, Liu L, Chen Q, Wang F, Li Q, Zeng Q, et al. Hypoxia with Wharton's jelly mesenchymal stem cells coculture maintains stemness of Umbilical Cord blood derived CD34+ cells . *Stem Cell Res Ther*, 2018; 9: 158.
 24. Sengenès C, Lolmede K, Zakaroff-Girard A, Busse R, Boulomie A. Preadipocytes in the human subcutaneous adipose-tissue display distinct features from the adult mesenchymal and haematopoietic stem cells. *J Cell Physiol*, 2005; 205: 114-22.
 25. McIntosh K, Zvonic S, Garrett S, Mitchell JB, Floyd ZE, Hammil L, et al. The immunogenicity of human adipose -derived cells: Temporal changes in vitro. *Stem Cells*, 2006; 24: 1246-53.
 26. Scherberich A, Di Maggio ND, McNagny KM. A familiar stranger: CD34 expression and putative functions in SVF cells of adipose-tissue . *World J Stem Cells*, 2013; 5: 1-8.
 27. Cuevas-Diaz-Duran R, Gonzalez –Garza MT, Cardenas-Lopez A, Chavez-Castilla L, Cruz-Vega DE, Moreno- Cuevas JE, Age related yield of adipose derived stem cells bearing the low affinity nerve growth factor receptor . *Stem Cells Int*, 2013; 2013: 372164.
 28. Calabrese G, Giuffrida R, Lo Furno D, Parrinello NL, Forte S, Gulino R, et al. Potential effect of CD271 on human mesenchymal stromal cell proliferation and differentiation. *Int J Mol Sci*, 2015; 16: 15609-15624.
 29. Dubey NK, Mishra VK, Dubey R, Deng YH, Tsai FC, Deng WP. Revisiting the advances in isolation, characterization and secretome of adipose -derived stromal/stem cells. *Int J Mol Sci*, 2018; 19: 2200.
 30. Shi YY, Nacamuli RP, Salim A, Longaker MT. The osteogenic potential of adipose -derived mesenchymal cell is maintained with aging . *Plast Reconstr Surg*, 2005; 116: 1686-696.
 31. McIntosh KR. Evaluation of cellular and humoral immune responses to allogenic adipose -derived stromal/stem cells. *Methods Mol Biol*, 2011; 702: 133-50.
 32. Mazini L, Rochette L, Amine M, Malka G. Regenerative Capacity of Adipose derived stem cells (ADSC), Comparison with Mesenchymal stem cells (MSCs). *Int J Mol Sci.*, 2019; 20: 2523.

33. Dhar S, Yoon ES, Kachgal S, Evan GRD. Long-term maintenance of neuronally differentiated human adipose-tissue derived stem cells. *Tissue Eng*, 2007; 13: 2625-632.
34. Othmani AE, Rouam S, Abbad A, Erraoui C, Harriba S, Boukind H, et al. Cryopreservation impacts cell functionality of long term expanded adipose derived stem cells. *J Stem Cell Res Ther*, 2019; 9: 445.
35. Klar AS, Zimoch J, Biedermann T. Skin Tissue Engineering: Application of adipose derived stem cells. *Biomed Res Int* 2017; 2017:9747010.
36. Merkle FT, Fuenetealba LC, Sanders TA, Magno L, Kessaris N, Alvafrez-Buyella A, et al. Adult neural Stem Cell in distinct microdomains generate previously unknown interneuron types. *Nat Neurosci*, 2014; 17: 207-14.
37. Weimann JM, Charlton CA, Brazelton TR, Hackman RC, Blau HM. Contribution of transplanted bone marrow cells to Purkinje neurons in human adult brains. *Proc Natl Acad Sci USA*, 2003; 100: 2088-2093.
38. Rajput BS, Chakrabarti SK, Dengare VS, Ramirez CM, Deb KD. Human Umbilical Cord mesenchymal stem cells in the treatment of Duchenne muscular dystrophy: safety and feasibility study in India. *J Stem Cells*, 2015; 10: 141-56.
39. Sato T, Iso Y, Uyama T, Kawachi K, Wakabayashi K, Omori Y, et al. Coronary vein infusion of multipotent stromal cells from bone marrow preserves cardiac function in swine ischemic cardiomyopathy via enhanced neovascularisation. *Lab Invest*, 2011; 91: 553-64.
40. Mashiko T, Takada H, Wu SH, Kanayama K, Feng J, Tashiro K, et al. Therapeutic effects of recombinant human collagen peptide bioscaffold with human adipose derived stem cells on impaired wound healing after radiotherapy. *J Tissue Eng Regen Med*, 2018; 12: 1186-94.
41. Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Coburn ML, Billigen JB, et al. Clinical outcomes of transplanted mesenchymal stem cells in stroke: a phase 1/2a Study. *Stroke*, 2016; 47: 1817-824.
42. Wu SH, Shirado T, Mashiko T, Feng J, Asahi R, Kanayama K, et al. Therapeutic effects of human adipose derived products on impaired wound healing in irradiated tissue. *Plast Reconstr Surg*, 2018; 142: 383-91.
43. Rochette L, Guenancia C, Gudjoncik A, Hachet O, Zeller M, Cottin Y, et al. Anthracyclines /tranzumab: new aspects of cardiotoxicity and molecular mechanisms. *Trends Pharmacol Sci.*, 2015; 36: 326-48.
44. Dalloz F, Maingon P, Cottin Y, Briot F, Horiot JC, Rochette L, et al. Effect of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defenses in the rat. *Free Radic Biol Med*, 1999; 26: 785-800.
45. Anderi R, Makdissy N, Azar A, Riuzk F, Hamade A. Cellular Therapy with human autologous adipose derived adult cells of stromal vascular fraction for alopecia areata. *Stem Cell Res Ther*, 2018; 9: 141.
46. Pal R, Venkataramana NK, Bansal A, Balaraju S, Jan M, Chandra R, et al. Ex-vivo expanded autologous bone marrow derived mesenchymal stromal cells in human spinal cord injury /paraplegia: a pilot clinical study. *Cytotherapy*, 2009; 11: 897-911.
47. Zhang J, Liu Y, Yin W, Hu X. Adipose derived stem cells in regulation of hematopoiesis. *Cellular and Molecular Biology Letters*, 2020; 25: 16.
48. Fang B, Song Y, Liao L, Zhang Y, Zhao RC. Favourable responses to adipose-tissue derived mesenchymal stem cells in steroid refractory acute graft versus host disease. *Transplant Proc*, 2007; 39: 3358-362.
49. Claudio-da -Silva C, Baptista LS, Carias RBV, Menezes Neto H, Da C Borojevic R. Autologous mesenchymal stem cells culture from adipose-tissue for treatment of facial rhytids. *Rev Col Bras Cir*, 2009; 36: 288-91.
50. Lee MJ, Kim J, Kim MY, Bae YS, Ryu SH, et al. Proteomic analysis of tumor necrosis factor alpha -induced secretome of human adipose tissue -derived mesenchymal stem cells. *J Proteomic Res*, 2010; 9: 1754-762.
51. Cheng H, Liu X, Hua R, Dai G, Wang X, Gao J, et al. Clinical observation of Umbilical Cord mesenchymal stem cells transplantation in treatment for sequelae of thoracolumbar spinal cord injury. *J Transl Med* 2014; 12: 253.
52. Dahbour S, Jamali F, Alhattab D, Al-Radaideh A, Abrabneh O, Al-Ryalat N, et al. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy. *CNS Neurosc Ther*, 2017; 23: 866-74.
53. Ebrahimian TG, Pouzoulat F, Squiban C, Buard V, Andre M, Cousin B, et al. Cell therapy based on adipose tissue -derived stromal cells promotes physiological and pathological wound healing. *Arterioscler Thromb Vasc Biol*, 2009; 29: 503-10.
54. Li X, Bai J, Ji X, Li R, Xuan Y, Wang Y. Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. *Int J Mol Med*, 2014; 34: 695-704.
55. Gao L, Gregorich ZR, Zhu W, Mattapally S, Oduk Y, Lou X, et al. Large cardiac patches engineered from human induced pluripotent cells derived cardiac cells improve recovery from myocardial infarction in swine. *Circulation*, 2018 Apr 17; 137(16): 1712-1730. doi: 10.1161/CIRCULATIONAHA.117.030785
56. Gu W, Nowak WN, Xie Y, Le Bras A, Hu Y, Deng J, et al. Single cell RNA and Metabolomics analysis reveal the contribution of perivascular adipose

- tissue stem cells to vascular remodelling. *Arterioscler Thromb Vasc Biol.*, 2019 Oct; 39(10): 2049-2066. doi: 10.1161/ATVBAHA.119.312732. Epub 2019 Jul 25.
57. Gao L, Kupfer ME, Jung JP, Yang L, Zhang P, Da Sie Y, et al. Myocardial tissue engineering with cells derived from human induced pluripotent cells and a native like high resolution 3 dimensional printed scaffold. *Circ Res.*, 2017 Apr 14; 120(8): 1318-1325. doi: 10.1161/CIRCRESAHA.116.310277.
 58. Kochegarov A, Lemanski LF. New trends in heart regeneration :A review. *J Stem Cells Regen Med.* 2016 Nov 29;12(2):61-68. eCollection, 2016.
 59. Jiang Y, Zhu W, Zhu J, Wu L, Wu G, Liu X. Feasibility of delivering mesenchymal stem cells via catheter to the proximal end of the lesion artery in patients with stroke in the territory of middle cerebral artery. *Cell Transplant*, 2013; 22: 2291-298.
 60. Wang S, Cheng H, Dai G, Wang X, Hua R, Liu X, et al. Umbilical Cord mesenchymal stem cells transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury. *Brain Res*, 2013; 1532: 76-84.
 61. Li JF, Zhang DJ, Geng T, Chen L, Huang H, Yin HL, et al. The potential of human Umbilical Cord derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. *Cell Transplant*, 2014; 23: 113-22.
 62. Nakamura K, Mieda T, Suto N, Matsuura S, Hirai H. Mesenchymal stem cells as a potential tool for spinocerebellar ataxia. *Cerebellum*, 2015; 14: 165-70.
 63. Cordes AL, Jahn K, Hass R, Schwabe K, Weissinger EM, Ganser A, et al. Intramedullary spinal cord implantation of human CD34+ Umbilical Cord derived cells in ALS. *Amyotroph Lateral Scler*, 2011; 12: 325-330.
 64. Hur JW, Cho TH, Park DH, Lee JB, Park JY, Chung YG. Intrathecal transplantation of Autologous adipose derived mesenchymal stem cells for treating spinal cord injury: a human trial. *J Spinal Cord Med*, 2016; 39: 655-664.
 65. Diez-Tejedor E, Gitiérrez-Fernández M, Martínez-Sánchez P, Rodríguez-Frutos B, Ruiz-Ares S, Lara ML, et al. Reparative therapy for acute ischemic stroke with allogenic mesenchymal stem cells from adipose tissue: a safety assessment: a phase II randomized, double-blind, placebo controlled, single center, pilot clinical trial. *J Stroke Cerebrovasc Dis.*, 2014; 23: 2694-2700.
 66. Tsai YA, Liu RS, Lirng JF, Yang BH, Chang CH, Wang YC, et al. Treatment of spinocerebellar ataxia with mesenchymal stem cells : a phase I/IIa clinical study. *Cell Transplant*, 2017; 26: 503-512.
 67. Vaquero J, Zurita M, Bonilla C, Fernandez C, Rubio JJ, Mucientes J, et al. Progressive increase in brain glucose metabolism after Intrathecal administration of Autologous mesenchymal stromal cells in patients with diffuse axonal injury. *Cytotherapy*, 2017; 19: 88-94.
 68. Vaquero J, Zurita M, Rico MA, Bonilla C, Aguayo C, Montilla J, et al. An approach to personalized cell therapy in chronic complete paraplegia The Puertade Hierro phase I/II clinical trial. *Cytotherapy*, 2016; 18: 1025-36.
 69. Schichinohe H, Kawabori M, Iijima H, Teramoto T, Abumiya T, Nakayama N, et al. Research on advanced intervention using novel bone marrow stem cell (RAINBOW): A study protocol for a phase , open label , uncontrolled , dose response trial of Autologous bone marrow stromal cells Transplantation in patients with acute ischaemic stroke. *BMC Neurol*, 2017; 17: 179.
 70. Wang L, Lu M. Regulation and direction of Umbilical Cord blood mesenchymal stem cells to adopt neuronal fate. *Int J Neurosci*, 2014; 124: 149-59.
 71. Mazzini L, Vercelli A, Ferrero I, Boido M, Cantello R, Fagioli F. Transplantation of mesenchymal stem cells in ALS. *Prog Brain Res*, 2012; 201: 333-359.
 72. Fernandez O, Izquierdo G, Fernandez V, Leyva L, Reyes V, Guerrero M, et al. Adipose -derived mesenchymal stem cells (AdMSC) for the treatment of secondary -progressive multiple sclerosis: a triple blinded , placebo controlled, randomized phase I/II safety and feasibility study. *PLoS ONE*, 2018; 13: e0195891.
 73. Staff NP, Madigan NN, Morris J, Jentoft M, Sorenson EJ, Butler G, et al. Safety of intrathecal Autologous adipose derived mesenchymal stromal cells in patients with ALS. *Neurology*, 2016; 87: 2230-234.
 74. Kong D, Zhang X, Wang D, Qu H, Jiang Y, Li X, et al. Umbilical Cord mesenchymal stem cells transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus. *Clin Lab*, 2014; 60: 1969-976.
 75. Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, et al. . Umbilical Cord mesenchymal stromal cells with Autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open label Clinical Study to assess safety and impact on insulin secretion. *Diabetes Care*, 2016; 39: 149-57.
 76. Dave SD, Vanikar AV, Trivedi HL, . Coinfusion of adipose derived mesenchymal stem cells- differentiated insulin making cells and haematopoietic cells with renal transplantation : a novel therapy for type 1 diabetes mellitus with end stage renal disease. *BMJ Case Rep*, 2013; 2013: 009901.
 77. Riordan NH, Ichim TE, Min WP, Wang H, Solano F, Lara F, et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. *J Transl Med*, 2009; 7: 29.
 78. Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus

- erythematosus: a pilot clinical study .Ann Rheum Dis., 2010; 69: 1423-429.
79. Fodor PB,PaulsethSG. Adipose derived stromal cells (ADSC)Injections for pain management of osteoarthritis in the human knee joint.Aesthetic Surg J, 2016; 36: 229-36.
 80. Song Y, Zhao HY,Lyu ZS,Cao XN,Shi MM,Wen Q,etal.Dysfunctional bone marrow mesenchymal stem cells in patients with poor graft function after Allogenic haematopoietic stem cells transplantation.Biol Blood Marrow Transplant, 2018; 24: 1981-989.
 81. Bernardo ME,Fibbe WE. Mesenchymal stromal cells and haematopoietic stem cells transplantation.Immunol Lett, 2015; 168: 215-21.
 82. Ball LM, Bernardo ME,,Roelofs H,Lankester A,Cometa A,Egeler RM, etal.Co transplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical haematopoietic stem cells transplantation. Blood, 2007; 110: 2764-767.
 83. Siegel G,Krause P,Wohrle S,Nowak P,Ayturan M,Kluba T, etal. Bone marrow derived human mesenchymal stem cells express cardiomyogenic proteins but do not exhibit functional cardiomyogenic differentiation potential. Stem Cells Dev, 2012; 21: 2457-470.
 84. Wu YM, Cao YB,Li XH,XuLX,Liu ZY, Liu B, etal. Transplantation of Umbilical Cord mesenchymal stem cells with haploidentical haematopoietic stem cells for 36 patients with refractory /relapsed myeloid leukemia .J Exp Haematol, 2014; 22: 1053-1057.
 85. Koh YG,Choi YJ,Kwon SK,Kim YS, Choi YJ,Tak DH. Adipose derived mesenchymal stem with microfracture versus cells microfracture alone :2 year follow up of a prospective randomized trial. Arthroscopy, 2016; 32: 97-109.
 86. Chen C,Qu Z,Yin X,Shang C,Ao Q,Gu Y,Liu Y.Efficacy of Umbilical Cord -derived mesenchymal stem cell-based therapy for osteonecrosis of the femoral head :a three year follow up study.Mol Med Rep, 2016; 14: 4209-215.
 87. Qu Z,Fang G,Cui Z, Liu Y.Cell therapy for bone non-union:a retrospective study .Minerva Mol, 2015; 106: 315-21.
 88. Garcia-Arranz M,Herreros MD, Gonzalez –Gomez C,De la Qantana P,Guadalajara H,Georgiev-Hristov T, etal.Treatment of Crohn’s Related rectovaginal fistula with allogeneic expanded adipose derived stem cells:a phase I/II clinical trial. Stem Cells Transl Med, 2016; 5: 1441-1446.
 89. Ringden O,Uzunel M,Rasmusson I,Remberger M,Sunberg M,Lonries H, etal. Mesenchymal stem cells for Treatment oftherapy resistant graft versus host disease. Transplantation, 2006; 81: 1390-397.
 90. Gao L, Zhang Y,Hu B, Liu J,Kong P,Lou S, etal. Phase II Multicenter , randomized, double blinded , controlled study of efficacy and safety of Umbilical Cord -derived mesenchymal stromal cells in the prophylaxis of graft versus host disease after HLA-haploidentical stem cells Transplantation.J Clin Oncol, 2016; 34: 2843-850.
 91. Chen G,Yang T,Tian H,Qiao M, Liu H,Fu C, etal.Clinical study of Umbilical Cord -derived mesenchymal stem cells for the treatment of nineteen patients with steroid resistant severe acute graft versus host disease.Chin J Haematol, 2012; 33: 303-306.
 92. Gonzalo-Daganzo R,Regidor C,Martin-Donaire T,Rico MA,Bautista G,Krsnik L, etal.Results of a pilot study on the use of third party donor mesenchymal stromal cells in Cord – blood Transplantation in adults. Cytotherapy, 2009; 11: 278-88.
 93. Macmillan ML,Blazar BR,DeFor TF,Wagner JE. Transplantation of ex vivo culture expanded parental haploidentical mesenchymal stem cells to promote engraftment of pediatric recipients of unrelated donor Umbilical Cord blood :results of a Phase I-II Clinical trial. Bone MarrowTransplant, 2009; 43: 447-54.
 94. Nesteruk J,Voronica N,Kundt G,Dunddorf P,Klopsch C,Kaminski A, etal. Stem Cell registry programme for patients with ischaemic cardiomyopathy undergoing coronary artery bypass graft::what benefits does it drive?ESC Heart Fail, 2017; 4: 105-111.
 95. Panfilov IA, DeJong R,Takashima SI,Duckers HJ. Clinical study using adipose derived mesenchymal –like stem cells in acute myocardial infarction and heart failure.Methods Mol Biol, 2013; 1036: 207-12.
 96. Wagner W,Wein F,Seckinger A,Frankhauser M,Wirkner U,Krause U, etal.Comparative characteristics of mesenchymal stem cells from human Bone Marrow, adipose tissue and Umbilical Cord blood .Exp Haematol, 2005; 33: 1402-416.
 97. Barlow S,Brooke G,Chatterjee K,Price G,Pulekanos R,Rossetti T, etal.Comparison of human placenta and Bone Marrow derived multipotent mesenchymal stem cells. Stem Cells Dev, 2008; 17: 1095-1107.
 98. Larijani B,Aghayan H,Goodarzi P,Mohamadi-Jahani-F,Nourozi –Javidan A,Dehpor AR, etal. Clinical Grade human adipose tissue-derived mesenchymal stem cells Banking .Acta Med Iran, 2015; 53: 540-46.
 99. Zanata F,Shaik S,Devi Reddy RV,Wu X,Ferreira LM,Gimble JM.Cryopreserved adipose tissue-derived Stromal/ stem cells:potential for applications in Clinic and Therapy .Adv Exp Med Biol, 2016; 951: 137-46.
 100. Shoshani O,Ullmann Y,Shupak A,Ramon Y,Gilhar A,Kehat I, etal.The role of frozen storage in preserving adipose tissue obtained by suction – assisted lipectomy for repeated fat injection procedures.Dermatol Surg, 2001; 27: 645-47.

101. Palumbo P, Lombardi F, Siragusa G, Cifone MG, Cinque B, Giuliani M. Methods of isolation, characterization and expansion of adipose derived stem cells (ASC's): An Overview. *Int J Mol Sci.*, 2018; 19: 1897.
102. Lee RH, Kim B, Choi I, Kim H, Choi HS, Suh K, et al. Characterization and expression analysis of Mesenchymal stem cells from human bone marrow and adipose tissue. *Cell Physiol Biochem*, 2004; 14: 311-24.
103. Kode JA, Mukherjee S, Joglekar MV, Hardikar AA. Mesenchymal stem cells: Immunobiology and role of Immunomodulation of tissue regeneration. *Cytotherapy*, 2009; 11: 377-91.
104. Gimble JM, Katz AJ, Burnell BA. Adipose derived stem cells for regenerative medicine. *Circ Res.*, 2007; 100: 1249-260.
105. Lee HC, An SG, Lee HW, Park JS, Cha KS, Hong TJ, et al. Safety and effect of adipose-tissue derived stem cell implantation in patients with critical limb ischemia: A pilot study. *Circ J.*, 2012; 76: 1750-760.
106. Lelek J, Zuba-Sharma EK. Perspectives for Future Use of Extracellular vesicles from Umbilical Cord –and adipose tissue-derived Mesenchymal stem/Stromal cells in Regenerative Therapies – Synthetic Review. *Int J Mol Sci.*, 2020; 21: 799.